Contact
searchSearch
HMP Global

RSV Vaccines Topic Center

Featured Article

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
Quiz
RSV Vaccine Eligibility
06/21/2023
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now...
06/21/2023
First Report Managed Care

Newsfeed

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
News
Patient-Reported Outcomes Drive Value-Based Care in Multiple Sclerosis
01/13/2025
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
Study Highlights the Substantial Economic and Health Care Burden of Vitiligo
01/13/2025
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
Quiz
Adapting Medicare Advantage Plans to Star Ratings in 2025
01/10/2025
With Medicare Advantage under increased scrutiny and Star Ratings impacting payments, how do you think plans will adapt in 2025?
With Medicare Advantage under increased scrutiny and Star Ratings impacting payments, how do you think plans will adapt in 2025?
With Medicare Advantage under...
01/10/2025
First Report Managed Care
News
COVID-19 Infection Linked to Increased Risk of Skin Conditions
01/08/2025
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that...
01/08/2025
First Report Managed Care
News
Provider Perceptions of Biosimilar Use in Oncology Networks
01/03/2025
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the...
01/03/2025
First Report Managed Care
News
Study Suggests Cognitive Impairment More Likely With Late-Onset Multiple Sclerosis
12/19/2024
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
News
Evaluating Long-Term Cost Benefits of Etranacogene Dezaparvovec in Hemophilia B Management
12/19/2024
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of...
12/19/2024
First Report Managed Care
News
Financial Hardships Associated With Long COVID Across Income and Education Levels
12/19/2024
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health...
12/19/2024
First Report Managed Care
News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care
FRMC Volume 21, Issue 4

Current Issue

October/November/December Volume 21, Issue 4, First Report Managed Care
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use